Drug intelligence / Profile preview

Dentavax

Development stage: Unknown
Lead developer: Muno-Vax Biotechnologies
Modality: Vaccines & Immunotherapeutics
Administration: Oral

Overview

Dentavax is an orally administered immunomodulatory supplement developed by Muno-Vax Biotechnologies that is marketed to support oral mucosal immunity and reduce gingivitis by enhancing local immune defenses in the gums.[6] It contains a harmless antigen preparation designed to stimulate specific components of the mucosal immune system, thereby helping to minimize inflammation of the gingiva and maintain gum and tooth health, but it is sold as a dietary supplement rather than an approved pharmaceutical drug for the treatment or prevention of periodontal disease.[6]

Brand names: Dentavax

Beyond the preview

Go deeper on Dentavax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dentavax.

Explore the full profile